Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2026
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1002/oby.70132 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Bone Health After Metabolic and Bariatric Surgery: Osteometabolism Biomarkers, Bone Mineral Density, and Microarchitecture Camila Medeiros de Almeida Karynne Grutter Lopes Michelle da Costa Tavares Bezerra Paulo Roberto Falcão Leal Eliete Bouskela Eduardo Medeiros Ferreira da Gama Maria Lucia Fleiuss de Farias Miguel Madeira Luiz Guilherme Kraemer‐Aguiar Obesity ABSTRACT Objective The effects of metabolic and bariatric surgery on bone health still require further investigation. Osteometabolism biomarkers, bone microarchitecture (BM), and mineral density (BMD) of patients who have undergone Roux‐en‐Y gastric bypass (RYGB) within 2–5 years from surgery were compared to non‐surgical age‐, sex‐, and BMI‐matched controls. Methods This cross‐sectional study included 39 patients following RYGB (BG: aged = 39 ± 5 years, BMI = 42.2 ± 3.8 kg/m 2 ) and 21 controls (CG). Circulating levels of albumin, calcium, phosphorus, magnesium, 25(OH) vitamin D, parathyroid hormone (PTH), carboxy‐terminal telopeptide of type 1 collagen (CTX‐1), and amino‐terminal propeptide of type 1 procollagen (P1NP) were assayed. BMD and BM were assessed by dual‐energy X‐ray absorptiometry (DXA) and three‐dimensional high‐resolution peripheral quantitative computed tomography system (HR‐pQCT). Results BG presented with higher circulating phosphorus, PTH, CTX‐1, and P1NP and lower 25(OH) vitamin D compared to CG. DXA parameters did not differ between groups. However, HR‐pQCT revealed significant derangements in BM (trabecular thickness, cortical bone density, and outer trabecular volumetric BMD) in BG. BG showed tibia‐specific trabecular microarchitecture impairment, while sex and BMI showed the expected associations with BM measures. Conclusions RYGB was associated with detrimental effects on osteometabolism biomarkers, as well as on density and structural parameters of BM. Early preventive strategies aimed at mitigating these deleterious effects should be systematically evaluated to minimize their long‐term impact. Trial Registration: ClinicalTrials.gov (NCT04193397) 10.1002/oby.70132 http://creativecommons.org/licenses/by/4.0/